Major research interests: Oxidative macromolecular damage of extracellular matrix in pathogenesis of renal and bone diseases;    urinary biomarkers of kidney diseases.


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Changes in the Fracture Resistance of Bone with the Progression of Type 2 Diabetes in the ZDSD Rat. Creecy A, Uppuganti S, Merkel AR, O'Neal D, Makowski AJ, Granke M, Voziyan P, Nyman JS (2016) Calcif Tissue Int 99(3): 289-301
    › Primary publication · 27209312 (PubMed) · PMC4961536 (PubMed Central)
  2. Pyridoxamine reduces postinjury fibrosis and improves functional recovery after acute kidney injury. Skrypnyk NI, Voziyan P, Yang H, de Caestecker CR, Theberge MC, Drouin M, Hudson B, Harris RC, de Caestecker MP (2016) Am J Physiol Renal Physiol 311(2): F268-77
    › Primary publication · 27194713 (PubMed) · PMC5008672 (PubMed Central)
  3. Decellularization of intact tissue enables MALDI imaging mass spectrometry analysis of the extracellular matrix. Gessel M, Spraggins JM, Voziyan P, Hudson BG, Caprioli RM (2015) J Mass Spectrom 50(11): 1288-93
    › Primary publication · 26505774 (PubMed) · PMC5320948 (PubMed Central)
  4. Pyridoxamine protects proteins from damage by hypohalous acids in vitro and in vivo. Madu H, Avance J, Chetyrkin S, Darris C, Rose KL, Sanchez OA, Hudson B, Voziyan P (2015) Free Radic Biol Med : 83-90
    › Primary publication · 26159508 (PubMed) · PMC4684779 (PubMed Central)
  5. 5'-O-Alkylpyridoxamines: Lipophilic Analogues of Pyridoxamine Are Potent Scavengers of 1,2-Dicarbonyls. Amarnath V, Amarnath K, Avance J, Stec DF, Voziyan P (2015) Chem Res Toxicol 28(7): 1469-75
    › Primary publication · 26046387 (PubMed) · PMC4996123 (PubMed Central)
  6. Cellular oxidative stress response mediates radiosensitivity in Fus1-deficient mice. Yazlovitskaya EM, Voziyan PA, Manavalan T, Yarbrough WG, Ivanova AV (2015) Cell Death Dis : e1652
    › Primary publication · 25695605 (PubMed) · PMC4669799 (PubMed Central)
  7. Hypohalous acids contribute to renal extracellular matrix damage in experimental diabetes. Brown KL, Darris C, Rose KL, Sanchez OA, Madu H, Avance J, Brooks N, Zhang MZ, Fogo A, Harris R, Hudson BG, Voziyan P (2015) Diabetes 64(6): 2242-53
    › Primary publication · 25605804 (PubMed) · PMC4439565 (PubMed Central)
  8. Alterations of urinary metabolite profile in model diabetic nephropathy. Stec DF, Wang S, Stothers C, Avance J, Denson D, Harris R, Voziyan P (2015) Biochem Biophys Res Commun 456(2): 610-4
    › Primary publication · 25499815 (PubMed) · PMC4287263 (PubMed Central)
  9. Diabetic nephropathy induces alterations in the glomerular and tubule lipid profiles. Grove KJ, Voziyan PA, Spraggins JM, Wang S, Paueksakon P, Harris RC, Hudson BG, Caprioli RM (2014) J Lipid Res 55(7): 1375-85
    › Primary publication · 24864273 (PubMed) · PMC4076088 (PubMed Central)
  10. A novel radioprotective function for the mitochondrial tumor suppressor protein Fus1. Yazlovitskaya EM, Uzhachenko R, Voziyan PA, Yarbrough WG, Ivanova AV (2013) Cell Death Dis : e687
    › Primary publication · 23788044 (PubMed) · PMC3702292 (PubMed Central)
  11. Site-specific AGE modifications in the extracellular matrix: a role for glyoxal in protein damage in diabetes. Voziyan P, Brown KL, Chetyrkin S, Hudson B (2014) Clin Chem Lab Med 52(1): 39-45
    › Primary publication · 23492568 (PubMed) · PMC4104777 (PubMed Central)
  12. Inhibition of integrin α2β1 ameliorates glomerular injury. Borza CM, Su Y, Chen X, Yu L, Mont S, Chetyrkin S, Voziyan P, Hudson BG, Billings PC, Jo H, Bennett JS, Degrado WF, Eckes B, Zent R, Pozzi A (2012) J Am Soc Nephrol 23(6): 1027-38
    › Primary publication · 22440900 (PubMed) · PMC3358756 (PubMed Central)
  13. Pyridoxamine protects protein backbone from oxidative fragmentation. Chetyrkin S, Mathis M, Hayes McDonald W, Shackelford X, Hudson B, Voziyan P (2011) Biochem Biophys Res Commun 411(3): 574-9
    › Primary publication · 21763683 (PubMed) · PMC3153140 (PubMed Central)
  14. Glucose autoxidation induces functional damage to proteins via modification of critical arginine residues. Chetyrkin S, Mathis M, Pedchenko V, Sanchez OA, McDonald WH, Hachey DL, Madu H, Stec D, Hudson B, Voziyan P (2011) Biochemistry 50(27): 6102-12
    › Primary publication · 21661747 (PubMed) · PMC3140462 (PubMed Central)
  15. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. Pedchenko V, Bondar O, Fogo AB, Vanacore R, Voziyan P, Kitching AR, Wieslander J, Kashtan C, Borza DB, Neilson EG, Wilson CB, Hudson BG (2010) N Engl J Med 363(4): 343-54
    › Primary publication · 20660402 (PubMed) · PMC4144421 (PubMed Central)
  16. Modification of collagen IV by glucose or methylglyoxal alters distinct mesangial cell functions. Pozzi A, Zent R, Chetyrkin S, Borza C, Bulus N, Chuang P, Chen D, Hudson B, Voziyan P (2009) J Am Soc Nephrol 20(10): 2119-25
    › Primary publication · 19608705 (PubMed) · PMC2754111 (PubMed Central)
  17. Pyridoxamine protects intestinal epithelium from ionizing radiation-induced apoptosis. Thotala D, Chetyrkin S, Hudson B, Hallahan D, Voziyan P, Yazlovitskaya E (2009) Free Radic Biol Med 47(6): 779-85
    › Primary publication · 19540915 (PubMed) · PMC2739572 (PubMed Central)
  18. Regulation of matrix synthesis, remodeling and accumulation in glomerulosclerosis. Pozzi A, Voziyan PA, Hudson BG, Zent R (2009) Curr Pharm Des 15(12): 1318-33
    › Primary publication · 19355971 (PubMed)
  19. Propagation of protein glycation damage involves modification of tryptophan residues via reactive oxygen species: inhibition by pyridoxamine. Chetyrkin SV, Mathis ME, Ham AJ, Hachey DL, Hudson BG, Voziyan PA (2008) Free Radic Biol Med 44(7): 1276-85
    › Primary publication · 18374270 (PubMed)
  20. Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: mechanism of action of pyridoxamine. Chetyrkin SV, Zhang W, Hudson BG, Serianni AS, Voziyan PA (2008) Biochemistry 47(3): 997-1006
    › Primary publication · 18161948 (PubMed)
  21. Pyridoxamine analogues scavenge lipid-derived gamma-ketoaldehydes and protect against H2O2-mediated cytotoxicity. Davies SS, Brantley EJ, Voziyan PA, Amarnath V, Zagol-Ikapitte I, Boutaud O, Hudson BG, Oates JA, Roberts LJ (2006) Biochemistry 45(51): 15756-67
    › Primary publication · 17176098 (PubMed) · PMC2597444 (PubMed Central)
  22. Glomerular injury is exacerbated in diabetic integrin alpha1-null mice. Zent R, Yan X, Su Y, Hudson BG, Borza DB, Moeckel GW, Qi Z, Sado Y, Breyer MD, Voziyan P, Pozzi A (2006) Kidney Int 70(3): 460-70
    › Primary publication · 16775606 (PubMed)
  23. Pyridoxamine lowers oxalate excretion and kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria. Scheinman JI, Voziyan PA, Belmont JM, Chetyrkin SV, Kim D, Hudson BG (2005) Urol Res 33(5): 368-71
    › Primary publication · 16292584 (PubMed)
  24. Designing a high throughput refolding array using a combination of the GroEL chaperonin and osmolytes. Voziyan PA, Johnston M, Chao A, Bomhoff G, Fisher MT (2005) J Struct Funct Genomics 6(2-3): 183-8
    › Primary publication · 16211517 (PubMed)
  25. Mechanism of perturbation of integrin-mediated cell-matrix interactions by reactive carbonyl compounds and its implication for pathogenesis of diabetic nephropathy. Pedchenko VK, Chetyrkin SV, Chuang P, Ham AJ, Saleem MA, Mathieson PW, Hudson BG, Voziyan PA (2005) Diabetes 54(10): 2952-60
    › Primary publication · 16186398 (PubMed)
  26. Pyridoxamine: the many virtues of a maillard reaction inhibitor. Voziyan PA, Hudson BG (2005) Ann N Y Acad Sci : 807-16
    › Primary publication · 16037308 (PubMed)
  27. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Voziyan PA, Hudson BG (2005) Cell Mol Life Sci 62(15): 1671-81
    › Primary publication · 15905958 (PubMed)
  28. Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria. Chetyrkin SV, Kim D, Belmont JM, Scheinman JI, Hudson BG, Voziyan PA (2005) Kidney Int 67(1): 53-60
    › Primary publication · 15610227 (PubMed)
  29. Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions. Voziyan PA, Khalifah RG, Thibaudeau C, Yildiz A, Jacob J, Serianni AS, Hudson BG (2003) J Biol Chem 278(47): 46616-24
    › Primary publication · 12975371 (PubMed)